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ABBREVIATIONS 
 
 AB - AB Blood Type 
 ABL -Abelson murine 
 ABO - Landsteiner's blood grouping system 
 ALL- acute lymphoblastic leukemia 
 AML- acute myeloid leukemia 
 AML1 -acute myeloid leukemia 1 
 ARID5B -AT-rich interactive domain-containing protein 5B 
 BCR – break point cluster region 
 BMI – body mass index 
 CALLA – common ALL antigen 
 CD – cluster of differentiation 
 CDKN1B -cyclin-dependent kinase Inhibitor 1b 
 CDKN2A -cyclin-dependent kinase Inhibitor 2A 
 CEBPE -CCAAT/enhancer binding protein (C/EBP), epsilon 
 CLL – Chronic lymphocytic leukemia 
 CML – chronic myeloid leukemia 
 CNS – central nervous system 
 CR –complete remission 
 CT – computed tomography 
 dl - decilitre 
 
 
 DNA – deoxyribo nucleic acid 
 EFS – event free survival 
 ERG -erythroblast transformation-specific related gene 
 ETV6 – translocation Ets(E26) leukemia virus6 
 FAB – French-american -british 
 FISH -Fluorescence in situ hybridization 
 Hb - hemoglobin 
 HDL – high density lipoprotein 
 HLA-DR -Human Leukocyte Antigen – DR 
 HOX 11- homebox 11 
 HOXA – homebox A 
 Ig - immunoglobulin 
 IGH -Immunoglobulin Heavy Locus 
 IKAROS – interplanetary kite-craft accelerated by radiation of the sun 
 IKZF1 – IKAROS Family Zinc Finger 1 
 IL3 – interleukin 3 
 JRA – juvenile rheumatoid arthritis 
 kgs - kilograms 
 L - litter 
 LAK - lakhs 
 LDH – lactate dehydrogenase 
 LSCS – lower segment caesarian section 
 LYL1 - lymphoblastic leukemia associated hematopoiesis regulator 1 
 
 
 mg - milligram 
 MLL -myeloid/lymphoid or mixed-lineage leukemia  
 mm 3 – cubic millimeter 
 MRD – minimal residual disease 
 MRI –magnetic resonance imaging 
 MYC -myelocytomatosis viral oncogene homolog 
 n- number 
 NHL –non hodgkins lymphoma 
 NOS – not otherwise specified 
 p – (petit)short arm of chromosome 
 PAX5 -Paired box protein -5 
 PBX1 – pre b leukemia transcription factor 1 
 Ph – Philadelphia translocation 
 q – long arm of chromosome 
 RBC – red blood cell 
 Rh - rhesus factor 
 RT-PCR -Reverse transcription polymerase chain reaction 
 RUNX1 –runt related transcription factor 1 
 SD – standard deviation 
 SGOT - serum glutamic-oxaloacetic transaminase 
 SGPT -Serum glutamic pyruvic transaminase 
 SVC – superior vena cava 
 t -translocation 
 
 
 TAL1 – T cell acute lymphocytic leukemia protein 1 
 TCF3 – transcription factor 3 
 TdT -terminal deoxynucleotidyltransferase 
 TLS – tumor lysis syndrome 
 TLX1 -T-cell leukemia homeobox protein 1 
 USG - ultrasonogram 
 WBC – white blood count 
 WHO – world health organisation 
 yrs - years 
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INTRODUCTION 
Leukemia is one among the most commonly seen malignancy in 
children. Leukemia is characterized by neoplastic proliferation of 
hematopoietic stem cells and accumulation of blasts and immature cells in the 
bone marrow. Leukemia is classified as lymphoid or myeloid depending on the 
lineage of the progenitor cells involved. Depending on the natural history, 
leukemia is again classified into acute leukemia and chronic leukemia. 
Acuteleukemiais classified into Acute Myeloid Leukemia (AML) and Acute 
Lymphoid Leukemia (ALL) (1). 
The classification of acute leukemiais based on the cellular involvement 
of the primary stem cell defect. Defect in the maturation and differentiation of 
common myeloid progenitor cells produces acute myeloid leukemia. Acute 
Myeloid Leukemia is characterized by clonal expansion of myeloid blasts. On 
the contrary acute lymphoblastic leukemia is due to the defect in the maturation 
and differentiation of common lymphoid progenitor cell. Acute lymphoblastic 
leukemia is characterized by clonal expansion of lymphoid blasts in peripheral 
blood, bone marrow and other tissues. 
More than 80% of the childhood cancer occurs in low and middle 
income countries. Cancer is the 9thmost common cause of death among 
children between 5 to 14 years in India (2). Leukemia contributes to 40-50% of 
total childhood cancer. Indian data shows ALL accounting for 75-80% of 
paediatric leukemia. Second highest incidence of childhood cancer in India 
occurs in tamilnadu, after Delhi (3, 4). 
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ALL is the one of the most common childhood malignancies. It accounts 
for approximately 25% of all childhood cancers and 75% of all leukaemia 
worldwide (5). 80% overall ALL occurs in children. About 2,500 to 3,500 new 
cases of ALL are reported in children each year in United States with an 
incidence of 31.9 cases per one million-person years. Most of the patients are 
younger than 5 years of age. ALL occurs in gender, age, ethnically and 
socioeconomically diverse population.  
Paediatric ALL is the first disseminated cancer shown to be curable. On 
the contrary adults who are affected by ALL are experiencing devastating 
disease. Worldwide, the curative rate of childhood ALL is 90% in contrast to 
adults with a curative rate of 40 %(1). In India 5 year survival rate is 
approximately 80 %( 5, 6). The cure rate in India is inferior to that of western 
countries. The reason for the low cure rate is manifold. These may include 
higher number of high risk population, limited data on cytogenetics, 
unfavourable cytogenetics to the drugs, increase incidence of relapse, febrile 
neutropenia, toxicity, and lower report of incidence and delayed diagnosis of 
disease(5). 
The key for cure and overall outcome is based on early diagnosis and 
early treatment. The initial response to the first few weeks of remission 
induction chemotherapy is of paramount importance in predicting the long term 
disease survival. Since most of the childhood ALL occur in developing 
countries, the initial symptoms are encountered by the general physician and 
not by hemato-oncologists. Inadequate therapy and poor outcome of treatment 
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are sometimes due to delayed referral. The earliest presentation of ALL is often 
nonspecific, mimicking the common and self-limiting illnesses. This varied 
presentation of ALL presents a diagnostic challenge to the front line 
physician(7, 8).Knowing the incidence and early presentation of the disease in 
the local population is essential for early referral and thereby initiation of early 
treatment in the children. Hence this study mainly concentrates on the varied 
clinical presentations of ALL in children to aid in early suspicion of disease, 
thus enabling prompt diagnosis. 
PATHOGENESIS  
ALL is a neoplasm of precursor hematopoietic cells, B lymphoblast and 
T lymphoblast, involving bone marrow or other tissues like lymph node, 
thymus, with or without peripheral blood involvement. ALL is clinically, 
morphologically, immunophenotypically and genetically a heterogeneous 
disease. 
ALL was thought to arise from exogenous or endogenous interactions, 
genetic susceptibility and chance mutation. This mutation causes 
developmental arrest of progenitor cells at a particular point in their 
differentiation and generates the capacity of uncontrollable self-renewal of cell. 
The first suggested causal exposure for childhood ALL is infection. The 
primary cause of paediatric ALL was chromosomal translocations occurring in 
utero during fet al haematopoiesis, the postnatal genetic events are the 
secondary contributors. Normal haematopoiesis and lymphoid development is 
disrupted by chromosomal rearrangements. Patient with trisomy 21, Klinefelter 
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syndrome and inherited diseases with excessive chromosomal fragility like 
Fanconi anaemia, Bloom syndrome and Ataxia telangiectasia have more risk 
for developing ALL. Acquired genetic changes is the most common 
mechanism of developing ALL whichis also said to be a hallmark of ALL(9, 10). 
It includes aberrant expression of oncoprotein, loss of tumour suppressor gene 
and chromosomal translocation that generate fusion gene encoding 
transcription factor or active kinase. 
 
 
Figure 1 
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Leukemic transformation of cells needs genetic & epigenetic changes in 
key growth regulatory pathway and co-operative mutation. Leukemogenesis 
also needs multiple signalling pathway distribution. Leukemogenesis pathway 
is shown in figure 1. Majority of ALL patients have no gross chromosomal 
alterations which is suggesting that sub microscopic genetic alterations are 
likely to contribute leukemogenesis. The common allelic variants which are 
associated with childhood ALL are IKZF1, ARID5B, CEBPE, and CDKN2A. 
Most frequent mutation seen in B cell ALL is PAX5 mutation. Function 
of PAX5 is encoding a paired domain protein which is required for the 
transition of pro B cell to pre B cell in B lineage. The second most frequent 
mutation is seen in IKZF1 gene. The IKZF1 gene encodes IKAROS zinc finger 
DNA protein. IKAROS zinc finger is needed for earliest lymphoid 
differentiation. 25% of B ALL shows t (12; 21) (p13; q22.3) translocation 
which usually have good prognosis. In this translocation ETV6 is fused to 
RUNX1. This translocation is often missed in routine karyotyping. 
Translocation t (1; 19) (q23.3; p13.3) is accounting for 5% of pre B ALL 
cases.PBX1 gene on chromosome 1q23.3 is fused with TCF3 gene on 
chromosome 19p13.3. The favourable cytogenetic patterns such as trisomies 
(trisomy 4 and 10) and translocation t (12; 21) are most common (9, 10, 11). 
Development of normal B cell and development of leukemia in B cell pathway 
is shown in figure 2 
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Figure 2 
  
Development and maturation of B lymphocyte 
And development of ALL in B cell lineage. 
(HSC – hematopoietic stem cell) 
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Genetic alteration are having considerable prognostic values in 
treatment outcome. Table 1 shows prognostic value of genetic abnormalities in 
ALL. 
 
Table 1 
B cell ALL  
Chromosomal 
abnormalities 
Genetic alteration Prognosis 
Trisomy 4, 10,17 - Favourable 
t(12;21) ETV6-PBX Favourable 
Hyperdiploidy - Favourable 
Hypodiploidy - Unfavourable 
t(4;11) MLL-AF4 Unfavourable 
t(9;22) BCR-ABL Unfavourable 
T cell ALL 
t(10;14) TLX1/HOX11 Favourable 
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Figure 3 
The NOTCH pathway mutation is seen in majority of T cell ALL. 
NOTCH1 is the regulatory protein which is synthesized as a single polypeptide 
protein. 60% of T cell ALL have activating mutation of NOTCH1(9, 10). Cell 
cycle gene namely deletion of CDKN2A, deletion of RB1 and mutation in 
TP53 and CDKN1B are also involved in T cell leukemogenesis. The TAL1 
gene deregulation is seen in 25% of T cell ALL. Other major group involved in 
T cell ALL leukemogenesis is homeobox gene. Overexpression of TLX1 
deregulation of HOX11L2 and HOXA gene cluster is seen in T ALL. The 
normal development of T cell lineage and development of ALL in T lineage is 
shown in figure 2. 
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The other genetic abnormalities and their frequencies are shown in figure 4(1) 
 
 
Figure 4 
 
   Frequency of specific genotype in childhood ALL. 
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RISK FACTOR 
Childhood ALL is a complex disease caused by a combination of 
genetic predisposition and environmental exposure. ALL is not an inherited 
disease and does not tend to run in families and so a family member having the 
disease will not increase risk of other persons in the family for getting the 
disease. But there are few genetically inherited syndromes that tend to increase 
the risk of ALL (11, 12). Genetic syndromes which have increased risk of 
developing ALL are as follows 
Down syndrome 
Fanconi anaemia 
Shwachman-diamond syndrome 
Bloom syndrome 
Ataxia telengiectasia 
Klinefelter syndrome  
Diamond –blackfan anemia 
Kostmann syndrome  
Li-fraumeni syndrome 
Severe combined immunodeficiency 
Paroxysmal nocturnal hemoglobinuria 
Neurofibromatosis type 1 
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Environmental risk factors 
Out of the various environmental risk factors, only one environmental 
risk factor that is ionising radiation has been significantly linked to ALL. Most 
other environmental risk factor are not consistently linked or weakly associated 
with childhood leukemia. The possible risks of leukemia from being exposed to 
minor level of radiation such as imaging modalities (x ray) are not well known. 
But whenever an individual is exposed to high level of ionising radiation such 
as being suspected to radiation therapy or being exposed an atomic blast are 
convincingly associated with increased risk of ALL(13). The other 
environmental risk factors which are of limited value in the development of 
ALL are as follows 
Non ionising radiation 
Alkylating agents -cyclophosphamide, ifosfamide, carboplatin, pesticide, 
Epipodophyllotoxin- etoposide, 
Teniposide, 
Benzen. 
 Some of the in-utero or fet al factors have considerable risk of 
developing ALL. Increased risk of developing leukemia is noted in babies who 
were having birth weight of more than 4 kgs(10, 37). Newer research says 
acceleration of foet al growth than the birth weights have strong association 
with developing ALL (38).  In utero exposures to X-ray have positive correlation 
with ALL.  
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PRESENTING CLINICAL FEATURES 
Even though it affects all age groups, the highest incidence of B cell 
precursor ALL is observed in children between 1 to 5 years of age (14). The peak 
incidence occurs between 3 to 4 years of age. Early peak is not seen in 
Americans and Africans and as a result ALL is more common with the children 
who are belonging to Caucasian descent. Children who are belonging to 
Hispanic ethnicity have the highest incidence of ALL, and polymorphism may 
contribute to both the increased risk of ALL for Hispanic children as well as 
their inferior outcomes (15). 
ALL is more common among males than females (16, 17). Patients with T 
cell ALL are tend to be older than with patients with B cell ALL.T cell ALL 
commonly affects the children belonging to median age group of 9 years and 
more commonly affects the male (75%) (18). 
Symptoms and signs 
Symptoms and signs occur because of bone marrow failure or the 
infiltration of medullary and extra medullary sites by leukemia. The onset of 
symptom is either insidious and slowly progressive over weeks to months or 
acute and explosive. In general, the more indolent the onsets of symptoms 
better the outcome. The varied clinical features of ALL are illustrated in  
figure 5.  
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Most common presenting complaints include fever, fatigue, lethargy, 
persistent, bruising or bleeding and bone pain. Lethargy and fatigue depends on 
the severity of anaemia. 
Fever is of infectious or non-infectious origin which is often treated with 
broad spectrum antibiotics. Fever usually resolves with chemotherapy. 
Thrombocytopenia may be the cause of bleeding and bruising. 
 
Figure 5 
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Bone pain is the most frequent presenting complaint which may occur as 
a result of bone marrow expansion, bone erosion, or leukemic periosteal 
involvement. Presenting complaint in young children will be gait disturbances 
or refusal to walk. Vertebral compression fractures may complicate generalized 
osteoporosis, leading to back pain. Prominent skelet al symptoms occur 
primarily in children without lymphadenopathy, organomegaly or leukocytosis 
and because of this presentation the diagnosis of ALL is delayed less 
commonly, bone pain are caused by recurrent episodes of bone marrow 
necrosis. Marrow necrosis is typically associated with a small leukemic burden 
and aleukemic blood picture. 5 percent of children with ALL may have bone 
pain or joint pain as a presenting symptom referred to rheumatology in 
suspicion of juvenile rheumatoid arthritis (JRA). Diagnosis is often delayed in 
these patients and the differentiation between ALL and JRA is critical to avoid 
pre-treatment with the corticosteroids. 
Physical findings include pallor, petechiae or purpura, mucous 
membrane bleeding and fever. Extra medullary leukemic spread may manifest 
by lymphadenopathy which will be present in 50% of patients. Organomegaly 
will be frequently noted in imaging or examination but rarely symptomatic. 
Skin involvement will be rarely seen. If present, it will manifest as cutaneous 
nodules which is often seen in pre-B cell phenotype. 
60% of patients with acute T cell ALL will have anterior mediastinal 
lymphadenopathy at the time of diagnosis which is rarely seen in children with 
B precursor ALL. The mediastinal mass of T cell ALL may be asymptomatic 
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and detected only on chest x-ray or may cause cough and dyspnoea on supine 
position. SVC syndrome occurs because of vascular compression by the 
anterior mediastinal mass, the clinical features will be facial swelling and 
plethora. Identification of symptomatic adenopathy is important prior to 
sedation for the diagnostic procedures such as bone marrow aspiration. 
Microscopic infiltration of testis by ALL is common in males and it 
requires no treatment. Overt testicular involvement with leukemia presents as 
painless diffuse or irregular enlargement of testis which is of less significance 
in prognosis due to the availability of modern treatment with intense therapy. 
CNS involvement will be seen in 2 to 3 percent of cases at the time of 
diagnosis and it is more commonly seen in patients with T cell ALL. Most 
patients with CNS involvement are asymptomatic and are only diagnosed with 
lumbar puncture. They are rarely symptomatic which includes headache, 
vomiting or cranial nerve palsies. 
LABORATORY AND RADIOGRAPHIC FEATURES 
60 percent of patients will have elevated WBC counts. Neutropenia will 
be frequently seen. Leukemic blasts are more commonly seen in patients with 
elevated WBC counts, they may be absent or found only after complete 
thorough review of blood smears from patients with decreased leukocyte 
counts. Increased WBC count of 50×109 /L is commonly associated with 
Lymphadenopathy, hepatosplenomegaly and T-cell immunophenotype. A 
WBC count more than 100×109/L is termed as hyperleukocytosis. 
Hyperleukocytosis associated ALL is rarely complicated by pulmonary 
insufficiency or intra cerebral haemorrhages. 
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Coagulopathies occur less commonly than AML but it is often 
associated with haemorrhagic or thrombotic complications. Coagulopathy 
commonly follows the administration of asparaginase and it is due to acquired 
anti-thrombin III deficiency leading to increased thrombin generation and it can 
be prevented by administration of anti-thrombin III 
Tumour lysis syndrome may be seen in patients with large leukemic cell 
burden with high rate of cell turnover. Tumour lysis syndrome is associated 
with multiple metabolic disturbances; the most prominent of it is increased 
levels of serum uric acid, which will lead to urate nephropathy. Acute renal 
failure which occurs as a result of urate nephropathy may rarely be seen in 
initial presentation of disease, but it commonly follows the initiation of the 
anti-leukemic treatment. Diminished renal function may be seen in cases with 
leukemic infiltration of kidneys or it can be due to obstructive uropathy due to 
enlarged lymph nodes. Hyperphosphatemia and secondary hypocalcemia may 
cause precipitation of calcium phosphate in renal tubules which is followed by 
renal failure and hyperkalemia which will lead to cardiac arrhythmias or 
asystole. Recombinanturicase will break down the uric acid which has 
improved the treatment of tumour lysis syndrome. Serum Lactic dehydrogenase 
levels are increased due to increased turnover of leukemic cells. Early 
identification of tumor lysis syndrome will prevent the early death and 
complication such as ARF and cardiac arrhythmias, the diagnostic criteria for 
tumor lysis syndrome is given in table 2. 
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Table 2 
TUMOR LYSIS SYNDROME–DEFINITION(19,20) 
LABORATORY –definition 
Two or more should be present within 3 days or up to 7 days following 
initiation of therapy 
Uric acid  
 
Phosphate 
Potassium  
Calcium 
Or ionised calcium 
Above the upper limit of normal range 
for age in children, >8mg/dl in adult 
>6.5 mg/dl in children, >4.5 mg in adult 
>6.0 mEq/L 
<7.0 mg/dl  
or <1.12 mg/dl 
CLINICAL– definition 
Kidney 
 
 
 
 
 
 
Cardiac  
Neurological  
Acute kidney injury 
Increase in serum creatinine of 0.3 
mg/dl (Or) Single value >1.5 timesthe 
upper limit of normal for age, in the 
absence of baseline value 
Oliguria –defined as an average urine 
output of <0.5 ml/kg/hours for 6 hours 
Arrhythmia , death 
seizure 
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Chest Radiographs of the patients with ALL will demonstrate anterior 
mediastinal mass in 5% to 10% of cases and it is most commonly seen in 
patients with T cell disease. The thymic masses are often associated with 
pleural effusion which are usually malignant and yield malignant cells in 
diagnostic thoracocentesis. Large mediastinal masses occurring in T cell ALL 
are medical emergency which requires careful monitoring and chemotherapy 
for preventing complications. 
Skelet al lesions are demonstrated in X rays/CT/MRI of more than 50% 
of patients. The most common skelet al manifestation include radiolucent lines 
in the metaphysis of long bones adjacent to the provisional zone of 
calcification. Generalized rarefaction of bones, cortical and trabecular 
osteolytic lesions and periosteal new bone formation can be seen. 
The presence of CNS disease at the time of diagnosis is an adverse 
factor in spite of intensification. Lumbar puncture will help in diagnosis of 
CNS involvement which will be present in 3% of children with ALL at the time 
of diagnosis. Cytocentrifugation (cytospin) of cerebrospinal fluid can be done 
in order to increase the diagnostic sensitivity by concentrating the low number 
of cells. 
CNS involvement will be categorized into three types shown in table 3 
The adverse prognostic significance associated with CNS2 disease. 
Traumatic lumbar puncture which have more than 10 erythrocyte/micro litre 
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and blasts at the time of diagnosis associated with increased risk of CNS 
relapse. 
 
Table 3 
Definition CNS for central nervous system involvement by leukemia 
Types Finding 
CNS 1 No blasts on cytospin 
CNS II    Blasts on cytospin but CSF WBC<5 cells/microlitre 
CNS III Blasts on cytospin with WBC>or=5 cells /microlitre 
 
 Some of the children with ALL show life threatening complication at 
the time of diagnosis. Overwhelming infection and gram negative sepsis are 
most frequent life threatening complication. Bleeding due to thrombocytopenia 
cause stroke, pulmonary haemorrhage and gastrointestinal haemorrhages. 
Electrolyte imbalance is the anticipated complication of ALL and it may be 
present at the time diagnosis also. It may occur as an isolated one or combined 
one. It may also indirectly indicate the tumour burden. Acute airway 
obstruction often needs immediate resuscitation measures. Leucostasis is the 
most frequent complication encountered in initial presentation which is due to 
high WBC count. Usually WBC count more than 100 × 109/L will cause 
increase plasma viscosity and causing circulatory stasis of leucocytes. The 
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Leucostasis may cause stroke in children or pulmonary haemorrhage and may 
cause heart failure (21).  
The complications and its underling pathology with the clinical 
presentation of those complications are summarised in table4 
Table 4 
Life threatening early complications 
Mechanism Complication Presentation 
Neutropenia Infection Overwhelming infection, 
gram negative sepsis with 
or without disseminated 
intravascular coagulation 
Thrombocytopenia Bleeding Stroke,  
pulmonary haemorrhage, 
gastrointestinal 
haemorrhage 
Electrolyte imbalance Blast lysis,  
acute renal failure 
Hyperkalaemia, 
hyperphosphatemia, 
hyperuricemia  
Reticuloendothelial 
infiltration 
Mediastinal thymic 
mass 
Acute airway obstruction 
Increased plasma 
viscosity secondary to 
high WBC (more than 
100 × 109/L) 
Leucostasis Stroke ,  
acute pulmonary oedema, 
heart failure 
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DIAGNOSIS 
Standard method of establishing diagnosis is by bone marrow aspiration 
and it also provides cells for morphological, histochemical, 
immunophenotypic, cytogenetic and molecular analysis.  
PERIPHERAL SMEAR  
Peripheral smear is the first and foremost clue for the diagnosis of ALL in 
children. Peripheral smear is the most economical way of initial screening of 
patients.FAB classification system had defined “acute leukemia as neoplasms 
with presence of 30% or more of blasts in peripheral bloodor bone marrow”. 
Many treatment centres considered ALL when there is more than 
25%lymphoblast in peripheral blood or bone marrow(22). 
Blasts have scant agranular cytoplasm, no Auer rods, coarse to fine 
chromatin, often indistinct nucleoli and no dysplastic myeloid cells. Others 
features commonly seen in ALL are leukoerythroblastosis with granulocyte 
precursors and nucleated RBCs, occasionally reactive lymphocytes and rarely 
marked eosinophilia 
BONE MARROW EXAMINATION  
Bone marrow examination is done for children showing less than 20% 
of blast in peripheral smear or those not showing blast in peripheral smear with 
classical clinical features suggestive of ALL. Slides should be stained with 
either Wright or Giemsa stain. The diagnosis of ALL is made when at least 
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20% lymphoblast are present in the bone marrow. Bone marrow hyper-
cellularity and infiltration by lymphoblast is characteristic. 
While doing bone marrow aspiration the utmost importance is provided 
for minimizing pain and fear of the child and the family, with the usage of 
conscious sedation or general anaesthesia. In case of ALL the marrow will be 
hyper cellular with replacement of fat spaces and normal marrow cells by 
means of leukemic infiltrates whereas in cases of AML the residual myeloid 
and erythroid precursors will appear morphologically normal. Megakaryocytes 
are reduced or absent in case of ALL. 
The bone marrow lymphoblasts appear more homogenous with respect 
to the morphologic and biological characteristics than those present in blood. In 
case of failure of bone marrow aspiration due to increased cell density biopsy 
should be done, in such cases few other diagnostic modalities like flow 
cytometry can be used. It can replace marrow morphology, examination of 
peripheral blasts when present in sufficient quantity 
FLOW CYTOMETRY 
Flow cytometry is an important diagnostic modality in leukemia. Itplays 
a major role in evaluation of leukemic patients. The cell suspension is passed 
through a flow chamber and the light scattered by individual cells is detected 
by a photo detector. Specific antibodies labelled with fluorescent dyes are used. 
These antibodies will bind to the antigen of interest and emit fluorescent light 
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upon excitation. This is detected by means of a photomultiplier tube and finally 
quantified. 
Flow cytometry enables rapid identification of ALL, quantification and 
immunophenotyping. It gives rapid and accurate diagnosis of ALL. Blood, 
bone marrow, lymph node, extra nodal tissues, and body fluids are used for 
flowcytometry. 
IMMUNOPHENOTYPING 
Immunophenotyping is an important tool in diagnosing ALL. It is also 
used for immunologic sub classification of ALL into T cell and B cell.                          
Immunophenotyping can be done by performing immunohistochemistry or by 
means of multiparameter flow cytometry (1, 9, 10). 
Immunophenotyping is based on the fact that different antigens which 
are expressed on the cells during each stage of normal haematopoiesis are also 
seen in the neoplasms that develop from the corresponding cells. Antigen 
expressed in B ALL and T ALL given in table 5. 
Table 5 
Immunophenotyping (1,9,10) 
Type Antigen expressed 
B-ALL CD19, CD79a, CD22, CD10, CD24, 
PAX5, TdT, CD20, CD34 
T-ALL CD1a, CD2, CD3, CD4, CD5, CD7, CD8, 
TdT, CD99, CD34. 
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CYTOGENETIC STUDIES  
Cytogenetic studies are needed to identify specific genetic alterations in 
leukemic blasts. Genetic alterations have the important prognostic value in 
ALL. 
Table 6 
Genetic abnormalities in Cytogenetic studies (9,10) 
Type of chromosomal 
abnormalities Cytogenetic abnormality 
Numeric abnormalities Hyper diploid 
  Diploid 
  Hypo diploid 
Structural abnormalities Pseudo diploid 
  t(9;22)(q34;q11) 
  t(8;14), t(8;2), and t(8;22) 
  t(4;11)(q21;q23) (and others involving 11q23) 
  t(1;19)(q23;p13.3) 
  4q11 abnormalities 
  7q35 abnormalities 
  Others 
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Cytogenetic studies gives the details of ‘ploidy’ which have important 
prognostic value. Cytogenetic studies detects the structural abnormalities in 
chromosome. Some of the cytogenetic abnormalities seen in ALL is tabulated 
in table 6 
MOLECULAR STUDIES 
 Molecular studies will identify translocations more rapidly, it is useful 
in cases which are not detected on routine karyotype analysis, and molecular 
studies are also used to distinguish lesions that appear cytogenetically identical 
but are molecularly different.  FISH, RT-PCR, Southern blot analysis are some 
of the examples for molecular studies used for subtyping ALL. Cytogenetic 
studies usually finds out changes in copy number or sequence of the nuclear 
DNA but molecular Genetic Expression Profiling is used to determine the level 
at which genes are expressed in samples compared with control. Expression 
profiling can be effective in classifying prognostically important subtypes 
including  BCR-ABL1, TCF3-PBX1, HYPERPLOIDY, 11q23/MLL 
rearrangement, ETV6-RUX1 and over expression of the Hox11 orphan 
homeobox gene which is detected in paediatric T-ALL was associated with 
excellent prognosis when treated with modern combination chemotherapy. 
GENOME-WIDE ASSOCIATION STUDIES  
Genomic wide association studies are emerging now recently. It can 
detect the presence of genetic changes which will not been found out by routine 
techniques e.g, activated tyrosine kinase pathways in Ph-like ALL, The clinical 
use of genome  wide association studies is limited. 
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CLASSIFICATION  
Classification of ALL plays a major role in choosing the treatment. The risk 
stratification method needs sub classification of ALL. Prognosis and treatment 
outcome are mainly dependent on the classification of ALL. 
MORPHOLOGICAL CLASSIFICATION 
The French-American-British classification is generally accepted 
morphological classification. According to the blast cell morphology, ALL is 
divided into L1 type, L2 type and L3 type (22, 23). FAB classification and its 
features are shown in table 7. 
Table 7 
FAB classification (22,23) 
ALL subtype Morphology Frequency 
L1 Small cell, scant cytoplasm, 
inconspicuous nucleoli 
85% 
L2 Pleomorphic large cell, more abundant 
cytoplasm, prominent nucleoli 
14% 
L3 Large round cell, Deeply basophilic 
cytoplasm and vacuoles 
1% 
 
Often the L1 and L2 blasts looks similar and are difficult to place on the 
classification. The revised FAB classification gives some histological score to 
distinguish the L1 type from L2 type. Histological scoring to distinguish the L1 
and L2 subtypes is shown in table 8 
27 
 
Table 8 
FAB scoring to distinguish L1 from L2(22,23) 
FAB type scoring: L1 v L2 Score 
Nuclear: cytoplasmic ratio high in > 75% cells  
Nuclear: cytoplasmic ratio low in > 25% cells 
Nucleoli absent or inconspicuous in > 75% cells 
 Nucleoli present in > 25% cells 
Irregular nuclear membrane in < 25% cells 
Irregular nuclear membrane in > 25% cells 
Large cells <50% of total 
Large cells > 50% of total 
Totals possible 
+1 
-1 
+1 
-1 
0 
-1 
0 
-1 
+2 to -4  
 
FAB type L1 = 0, 1, + 2; L2 = -, 2,-3,-4  
 
Due to advancement in immunophenotype studies, the FAB classification is no 
longer used (23) 
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IMMUNOPHENOTYPIC CLASSIFICATION 
Immunophenotyping is done by flow cytometry with antigens 
expression in blast cells. The markers for various lineage is shown in table 9 
Table 9 
Immunophenotyping marker  
B lymphoid markers T lymphoid markers Multi-potent stem cell 
markers 
CD19, CD10, CD20, 
CD22, cCD79a 
CD3, CD5, CD7, 
CD1a,CD2, CD4, CD8, 
CD10, Cyt CD3 
CD45, CD34, HLA-DR, 
TdT 
 
 
For pro B ALL, CD 22 is more sensitive marker. CD10 is expressed in 
both lineage but more frequently expressed in B cell lineage than T cell 
lineage. It has significant prognostic value. CD10 expression in T cell ALL 
have good outcome and it can be taken as an independent prognostic factor 
regarding T cell ALL. But, in B cell ALL, CD10 cannot be taken as 
independent prognostic parameter(23). 
 
WHO CLASSIFICATION 
WHO proposed a classification based on morphology and cytogenetic 
profile in 1997 which was revised in 2008.Burkitt – cell leukemia was 
eliminated in 2008 WHO classification. According to WHO 2008 classification 
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three broad groups can be distinguished: precursor B-cell ALL, mature B-cell 
ALL and T-cell ALL. The guidelines mainly focus on precursor B-cell ALL 
and T-cell ALL, The sub classification of B-cell ALL are B-lymphoblastic 
leukemia/lymphoma, not otherwise specified (B-cell ALL NOS) and B-
lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities. The 
B-cell ALL NOS may be divided further into early pre B-ALL, ALL and pre 
B- ALL. The sub-classification of precursor T-cell ALL is early T-cell ALL 
(pro T-cell ALL and pre T-cell ALL), cortical (thymic) T-cell ALL and 
medullary (mature) T-cell ALL (13). B cell sub classification and characteristics 
are shown in table 10.  
Table 10 
B cell ALL sub classification by WHO  
ALL - Subtype  Characteristics  
B-Cell ALL NOS  
Early Pre-B ALL/pro 
B-ALL  
CD19+, cCD79a+, cCD22+, nuclear TdT positive, 
CD10- 
Common ALL  CD10 (CALLA)  
Pre-B ALL  Cytoplasmic IgM, CD19+, CD79a+, CD22+, 
CD10+  
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Cytogenetic abnormalities of ALL of WHO classification showed in table 11, 
table 12 and table 13. 
Table 11 
cytogenetic abnormalities(9,10) 
Hyperdiploidy >50 and usually <66 chromosomes without structural 
abnormalities. Non-random: chromosomes 21, X, 14 and 
4 most common; chromosomes 1, 2 and 3 being the least 
common. CD19+ve, CD10+. CD34+ (most cases)  
CD45 –ve (often). Patients with T-ALL should not be 
considered part of this group.  
Hypodiploidy  < 44 – 46 chromosomes. Structural abnormalities are 
uncommon. CD19+, CD10+ Diagnosis may be missed by 
standard karyotyping due to endoduplication.  
t(9;22)(q34;q11.2); 
BCR-ABL1  
CD10, CD19, TdT positive, May express CD13/CD33. 
CD25 highly associated with t (9; 22). p190 transcript 
(most childhood cases) p210 transcript (50% of adult 
cases)  
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Table 12 
cytogenetic abnormalities (9,10) 
t(v;11q23); MLL  Most common leukemia in infants. Short latency period.  
High WBC, CNS involvement. Pro-B immunophenotype  
CD19+, CD10 –ve, CD24 –ve, CD15+ve  
Neuroglial antigen-2 (NG2) relatively specific.  
t(12;21)(p13;q22); 
TEL-AML1 
(ETV6-RUNX1)  
Rare in adulthood. CD19+ve, CD10+ve, CD34 +ve (commonly) 
May have near or complete absence of CD9/CD220/CD66c. 
Myeloid antigens (CD13) frequently expressed. ?necessary but 
sufficient for leukemic translocation?  
t(5;14)(q31;q32);IL
3-IGH  
Constitutive expression of IL-3 gene.  
Associated with eosinophilia which is reactive and not part of 
the leukemic clone. Diagnosis may be based on 
immunophenotype and genetic findings even if the bone marrow 
blast count is low. CD19+, CD10+  
t(1;19)(q23;p13.3); 
E2A-PBX1 (TCF3 
– PBX1)  
CD19+, CD10+, cytoplasmic M heavy chain.  
Strong expression of CD9 Lack of CD34 or very limited CD34 
expression.  
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Table 13 
cytogenetic abnormalities(9,10) 
T-Cell ALL  
Precursor T- ALL  CD1a, CD2, CD3, CD4, CD5, CD7 and CD8.  
CD7 and cCD3 are most often positive.  
CD3 is lineage specific,  
CD4 /CD8 are frequently co-expressed;  
CD10 may be positive; CD79a (10% of cases)  
CD13/CD33 (19-32% of cases).  
Pro T-cell ALL  cCD3+, CD7+, CD2-,CD1a-, CD34+/-; CD4-, CD8-  
Pre T-cell ALL  cCD3+, CD7+, CD2+, CD1a-, CD34+/-; CD4-, CD8-  
Cortical T-cell ALL  cCD3+, CD7+, CD2+, CD1a+, CD34-; CD4+, CD8+  
Medullary T-cell 
ALL  
cCD3+, CD7+, CD2+, CD1a-, CD34-, sCD34+; CD4+ 
or CD8+  
 
2016 WHO classification is not a new classification rather it is the 
revision of 2008 publication based on the new knowledge of this disorder 
obtained since 2008.In this 2016 version to the list of recurrent genetic 
abnormalities two new provisional entities were added and the hypodiploidy 
was redefined as “either low hypodiploidy or hypodiploidy with TP53 
mutation” (24). The 2016 update WHO classification on ALL is shown in table 
14 & 15 
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Table 14 
WHO classification – 2016 update(24) 
B-lymphoblastic leukemia/lymphoma 
B-lymphoblastic leukemia/lymphoma, NOS 
B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities 
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 
B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged 
B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-
RUNX1 
B-lymphoblastic leukemia/lymphoma with hyperdiploidy 
B-lymphoblastic leukemia/lymphoma with hypodiploidy 
B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH 
B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 
B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like(Provisional entity: 
B-lymphoblastic leukemia/lymphoma with iAMP21(Provisional entity) 
Table 15 
WHO classification – 2016 update(24) 
T-lymphoblastic leukemia/lymphoma 
  Early T-cell precursor lymphoblastic leukemia(Provisional entity) 
(Absence of CD1a/CD8, weak expression of CD5 Presence of 1 or more 
myeloid or stem cell markers (CD117, CD34, HLA-DR, CD13, CD33, CD11b, 
or CD65)) 
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TREATMENT  
Previously ALL remained to be a fatal childhood disease until effective 
pre symptomatic central nervous system therapy was developed in the year of 
1960s. Even though combination chemotherapy provided frequent remissions, 
(disappearance of microscopically detectable leukemia in the bone marrow 
with recovery of marrow function), the appearance of leukemic cells in the 
CNS was common and the marrow relapse will occur despite further 
management). 
Post induction intensification therapy has increased the 5 year event free 
survival (EFS) from 50% to nearly90% for children who are younger than 
15years of age and it allowed replacement of cranio spinal radiation for most of 
the patients with an intra thecal therapy. Unlike other paediatric cancers 
curative therapy is available for ALL, outcomes are excellent with prolonged 
treatment which will be extended for 2 to 3 years or more than that. Treatment 
is tailored according to the risk of relapse, patients who are at the high risk of 
relapse will obtain  aggressive treatment, whereas who are at low risk of 
relapse will obtain good outcomes even with less morbid treatment. Response 
to the induction therapy is assessed by multi parameter flow cytometry or PCR 
–based technology, now it supplements presenting clinical features and 
cytogenetic for treatment allocation. 
The risk based stratification is one of the hallmark of the treatment of 
childhood ALL. This classification done based on risk of treatment failure with 
the features consistently affect prognosis. An Indian Childhood Collaborative 
Leukaemia Group Study for Childhood Acute Lymphoblastic Leukaemia gives 
risk stratification strategy which shown in table 16and table 17. 
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Table 16 
RISK STRATIFICATION FOR T cell ALL 
Standard Risk(SR) High Risk(HR) 
WBC count of <100,000mm3  
No bulky disease  
Not ETP-ALL  
Prednisolone Good responder 
CR at the end of induction.  
 
WBC count ≥100,000/mm3  
Prednisolone poor responder 
Bulky disease  
ETP immunophenotype  
T-NHL  
No CR after induction.  
 
Table 17 
RISK STRATIFICATION FOR B cell ALL 
Standard Risk(SR) Intermediate Risk(IR) High Risk(HR) 
Age >1 and <10 years  
Non T-cell  
Prednisolone Good 
Responder  
No high risk cytogenetics  
WBC <50,000/mm3  
MRD <10-3 after 
induction  
Complete Remission after 
induction  
No CNS disease  
 
Good risk features but 
age ≥10 years  
Good risk features but 
WBC ≥50,000/mm3  
Good risk features but 
bulky lymph nodes*  
MRD <10-3 after 
induction  
No High Risk criteria  
 
All prednisolone poor 
responders, irrespective 
of age and presenting 
WBC count  
High risk cytogenetics  
CNS disease   
MRD ≥10-3 after 
induction  
 
*(≥5 cm in peripheral region and in chest >5 cm on CT scan or occupying 
≥1/3rd diameter on chest x-ray) and/or bulky liver/spleen reaching beyond 
midway to umbilicus and/or presence of testicular disease  
 
 
36 
 
PHASES OF TREATMENT  
ALL treatment approach varies to various risk groups. The key elements 
for treatment protocol includes remission induction, early intensification,  
consolidation, therapy directed to CNS, delayed intensification, continuation or 
maintenance therapy and allogeneic bone marrow transplantation. 
Child should receive hyperhydration and allopurinol as soon as the 
diagnosis is made. This therapy minimizes the metabolic complications. 
REMISSION INDUCTION  
The goal of remission induction is to restore the normal hematopoiesis. 
This is done by rapid eradication of leukemic cell burden almost by 99%. This 
is achieved by three drug combination therapy which include glucocorticoid 
(prednisolone or dexamethasone), vincristine and L-asparginase. 
Remission is defined by “less than 5% blast in marrow and return of 
neutrophil and platelet counts to near normal levels after 4-5 weeks of 
treatment”(1). 
CONSOLIDATION 
The goal of the consolidation therapy isto eradicate the sub microscopic 
residual disease that remains after complete remission, to maintain the 
remission in bone marrow and to reduce the risk of CNS relapse. This phase of 
chemotherapy involves combinations of different chemotherapeutic agents to 
maximize synergy and minimize drug resistance High dose systemic 
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methotrexate in parallel with intrathecal chemotherapy is used for 
consolidation. Other drugs are also which are mercaptopurine, thioguanine, 
cyclophosphamide, etoposide, and cytarabine. 
INTENSIFICATION THERAPY  
Intensification therapy is given mainly for high risk group of children. It 
can be associated with interim maintenance therapy. It will reduce the risk of 
relapse. It can increase the estimated 5 year survival rate compared with 
standard intensity treatment.  It consists of reinduction and repetition of early 
induction phase.  
MAINTENANCE THERAPY 
Aim of maintenance therapy is reduce the minimal residual cells which 
are not detectable in current diagnostic technique. The therapy can continued 
up to two to three years. High incidence of relapse seen in children who had 
maintenance therapy of less than two years. The cornerstone of maintenance 
therapy is antimetabolite therapy with methotrexate and mercaptopurine. 
Continuous maintenance schedule have longer remission than interrupted 
maintenance schedule.    
THERAPY DIRECTED AGAINST THE CNS 
Although bone marrow remission could be achieved by using systemic 
chemotherapy, most children eventually develop CNS relapse in the absence of 
specific therapy directed toward CNS. Several methods are used to eradicate 
the CNS disease.  
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Intrathecal chemotherapy is one method to eradicate CNS disease which 
includes administration of intrathecal methotrexate or a combination of 
intrathecal methotrexate, cytarabine, and hydrocortisone (known as triple 
intrathecal agents). The other method is systemic administration of 
chemotherapy which includes dexamethasone, high-dose methotrexate, 
cytarabine, and asparaginase and cranial radiation 
Summary of the treatment phases and duration is given in table 18. 
Table 18 
Phases of ALL treatment. 
Phases  Goal Duration 
Remission induction Rapid eradication 
Restoration of normal 
hematopoiesis 
4-6 weeks 
Consolidation and therapy 
directed to therapy 
To strengthen the 
remission in bone marrow  
Provide CNS prophylaxis 
4-12 weeks 
Intensification Reducing the risk of 
relapse 
8-12 weeks 
Maintenance/continuation 
therapy 
Reduce the minimal 
residual cells 
2-3 years 
Allogeneic bone marrow 
transplantation  
 
Elimination of residual 
leukemic cells in high risk 
subtypes refractory to 
chemotherapy 
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ALLOGENEIC BONE MARROW TRANSPLANTATION  
Allogeneic bone marrow transplantation is advised to whom are 
refractory to chemotherapy. Total body irradiation and cyclophosphamide is 
used for myeloablation. Allogeneic hematopoietic stem cells are administered 
intravenously. 
Allogeneic stem cell transplantation is the treatment which is also 
recommended for high-risk patients in complete remission. Philadelphia-
chromosome-positive ALL patients have improved results with allogeneic bone 
marrow transplant. 
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REVIEW OF LITRATURE 
1. Pandian G et al (2018) did a prospective study in 31 children who are 
diagnosed as leukaemia and treated for 3 years in GRH Madurai. Detailed 
history, clinical examination and lab investigations were done for those 
patients. The results of their study are ALL was the commonest leukaemia in 
children. Fever was the most common symptom, hepatosplenomegaly was the 
most common sign, T-cell leukaemia had worse prognosis compared to B-cell 
leukaemia and B- cell ALL was more common than T-cell ALL. Extra 
medullary organ involvement is an indicator of increased tumour burden and 
worse prognosis. Clinical and laboratory parameters did not predict the 
outcome in their study (25). 
2. Siddaiahgari SR et al (2015) did an observational study on 103 
children in tertiary health centre, India. The result of the study showed that 
initial symptoms will occur in children aged between 2 to 5 years, common 
clinical features are fever followed by pallor, hepatomegaly and splenomegaly. 
Most of the children in this study belong to standard risk according to their age, 
immunophenotyping, white blood cell count and cytogenicity(6).  
3. Shalal HH et al (2017) conducted a retrospective study in 55 patients 
to show the initial presenting features of children with ALL. Fever and pallor 
were the most common features. Cutaneous bleeding, hepatosplenomegaly, 
lymphadenopathy, facial palsy, bone pain, anorexia, anaemia, mucocutaneous 
bleeding were the other features (7). 
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4. Guru FR et al (2018) conducted an observational study in the year 
between June 2008 to November 2013. In their study they evaluated the 
survival outcome in children with ALL and they determined prognostic factors 
like immunophenotyping, cytogenetic factors in addition to conventional 
factors which are associated with adverse outcome. Their studies clearly 
showed the prevalence of adverse prognostic factors were not very high in 
Indian population like which had been reported in previous Indian studies (5). 
5. Sousa DW et al (2015) conducted a study in 76 patients who are 
under 19 years old and diagnosed as ALL. The result of their study showed that 
the most prevalent age group was 1-9 years, under 1 year old and over 9 year 
old patients accounted for 2.6 and 22.4 % respectively. Patients who were less 
than 1 year are associated with unfavourable prognostic factors. The 
unfavourable prognostic factors were high base line WBC count, pro B 
immunophenotype, and CD10 negativity. Patients who are between 1 and 9 
years were associated with more favourable prognostic factors. The favourable 
prognostic factors were WBC count less than 50 x 109 cells /L, CD10 
positivity, and DI >1.16. Commonly encountered clinical features were 
hepatosplenomegaly, fever and lymphadenopathy. CNS involvement and 
mediastinal masses were observed in 6.6 and 11.6% respectively. Anaemia was 
found in 85% of patients. B-immunophenotype ALL was found in 89.5% of 
patients, T-immunophenotype was found in 10.5% of patients (26). 
6. Arya LS et al (2010) did a retrospective study in 60 children with  
T-cell ALL and 139 children with B-cell lineage ALL. The aim of their study 
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was to assess the clinical features, prognostic factors and outcome of childhood 
T-cell ALL in comparison with B-lineage ALL. The results were T- cell ALL 
was observed in 30% of cases. High risk factors at presentation were more than 
and equal to 10 years, WBC count > 50,000/mm3, mediastinal masses and CNS 
leukemia. These high risk factors were more commonly seen with T-cell ALL 
compared to B lineage ALL. Even though high risk factors were commonly 
seen with T-ALL, the survival outcome was similar to B-lineage patients (18). 
7. Pahloosye A et al(2011) conducted a prospective follow-up study of 
100 patients in shahidsadoughi hospital in the period between march 2006 to 
February 2010. All the children included in this study showed abnormal blood 
count and 27% of children had pancytopenia, 37% had leukopenia, 38% had 
leucocytosis. White blood cell count of more than50000/mm3was detected in 
22% of the children and 85% of children had anaemia. Most common 
presenting symptoms were lethargy, malaise, anorexia, pallor and fever. T cell 
ALL occurred more frequently compare to B cell ALL in this study group (17). 
8. Khalid S et al (2015) reviewed the clinical details and treatment 
outcome of children in newly diagnosed acute lymphoblastic leukaemia. They 
did a retrospective study in children who were diagnosed with ALL and 
evaluated those patients for 17 years and the data was collected. 46 patients 
were diagnosed to have ALL during the study period and were on regular 
follow up. 45 of these were in complete remission after induction therapy for 
28 days, 30 patients were doing well during the study period, among these 30 
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patients 26 remained relapse free, while only 4 got disease relapse, remaining 
16 patients did not survive in whom 11 got disease relapse.(27) 
9. Li SY et al (2015) compared the clinical features of ALL in male and 
female patients in southern china. 705 subjects were included in their study. 
Male were younger compare to female at the time of diagnosis. Male 
predominance was noted among the study group. Most frequently occurred 
blood group among the subjects is O blood group and also B-cell 
immunophenotype was most frequent than T-cell ALL immunophenotype and 
ALL most commonly presented between 2 years to 4 years (28). 
10. Ahirwar R et al (2018) did this study to find out the actual incidence 
of four major types of leukaemia which are prevalent in India. Total 73 cases 
(in and out patients) were included in his study, out of those 73 cases on final 
diagnosis 23 patients had ALL, 11 cases had AML, 35 cases had CML, 1case 
had CLL and 3 were undiagnosed. Those undiagnosed cases were referred to 
tertiary care centre. His study revealed that the chronic leukaemia was more 
common than acute leukaemia. Among which chronic myeloid leukaemia was 
the most common type followed by acute lymphoblastic leukaemia, 
acutemyeloblasticleukaemia and chronic lymphocytic leukaemia respectively 
(29).   
11. Khan AH et al (2015) conducted a prospective study in 75 cases who 
presented to oncology OPD and were diagnosed and documented to have acute 
leukaemia during the period from January 2009 to December 2011. Among 75 
cases who were included in their study period AML comprised of 31 cases, 
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ALL comprised of 40 cases and biphenotypicleukaemia comprised of rest 4 
cases. Out of 40 cases of ALL 29 cases had B-cell phenotype, the rest 11 cases 
had T-cell phenotype. B-cell ALL was commonly seen in children constituting 
75.8%, while T-cell ALL was predominantly seen in adults. 
Immunophenotypic analysis revealed that the pro B-cell phenotype was 
encountered in 22 cases, mature B-cell in 7 cases and T-cell in 11 cases (23). 
12. Sidhom I et al (2008) conducted a study in 67 patients who were 
newly diagnosed to have T-cell ALL. These patients were recruited from 
children’s cancer hospital from Egypt during the time period of July 2007 to 
June2008. The results of their study were the frequency of CD34 was 34.9%, 
CD10 was 33.3%, while CD13/CD33 was 18.8%. There was no significant 
association encountered between CD34, CD10 or myeloid antigen positivity 
and presenting clinical features such as age, sex, TLC and CNS leukaemia. (30) 
13. Anoop c et al (2016) did a retrospective analysis in southern India to 
determine the profile of ALL in children up to 2 years of age. Male 
predominance was observed and 18% of ALL was noted in infants. Fever was 
the most common presenting symptoms followed by pallor and 
hepatosplenomegaly. 35% of children had Severe anaemia (haemoglobin<7gm 
%), 28% had more than 50000/mm3 of WBC count and severe 
thrombocytopenia was noted in 20% of study population. Elevated LDH and 
uric acid was seen in 64% and 11.5% respectively. B cell immunophenotype 
most commonly occurred than T cell immunophenotype (31). 
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14.Badira, C.P et al (2016) did a retrospective study about the clinical 
profile and outcome of early T-cell precursor ALL. Their study result showed 
occurrence of Early T-cell Precursor ALL among T cell ALL was 16% with 
male predominance. Hyper leucocytosis was observed in 36.7%. Higher 
median age and minimal disease burden was noted in Early T-cell Precursor 
ALL in this study (32).  
15. Baviskar JB et al (2016) conducted a prospective and retrospective 
study in 156 patients over a period of 5 years between may 2006 to may 2011. 
Diagnosis of ALL was based on peripheral blood count, peripheral blood smear 
and bone marrow examination for morphology. Cytochemistry study was done 
whenever required. In their study the commonest leukaemia was CML, 
followed by ALL, AML and then CLL. Out of 156 cases 90 were male and 66 
were female. ALL was the most common type of leukaemia in children and 
adolescents whereas myeloid leukaemias were common in adults (14). 
16. Kulkarni KP et al (2013) did a study to assess the gender ratio of 
ALL at a tertiary care centre in India. Their study result reported that male 
predominance was observed in childhood ALL in Indian population. This male 
predominance is not significantly different compare to world population (16). 
17. Tavasolian et al (2014) carried out a case control study to establish 
the relationship between ABO blood group and ALL. Case and control group 
consist of 293 and 300 cases respectively. Their study result was AB blood 
group population was having higher risk of ALL compared to other blood 
group (33). 
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18. Kumar N et al (2017) did a retrospective analysis of nutritional 
status in 51 children who had completed the treatment in tertiary centre, south 
India. Nearly 50% of study population shows under nutrition at the time of 
diagnosis obviating the need for nutritional rehabilitation.  Few children are 
becoming overweight and obese during the course of treatment signifies the 
need for modification in lifestyle and endocrine evaluation (34). 
19. Yhigashiyama et al (2014) did a retrospective study to assess the 
nutritional status of ALL patients during chemotherapy.  23 patients who were 
diagnosed to have ALL are included in this study. At the time of diagnosis, 
8.7% were underweight and 21.7% were overweight according to BMI Z score. 
According to waterlow score five patients were underweight and 3 were 
overweight, the prevalence of malnourished children did not change 
significantly during treatment (35). 
20. Adelmen AS et al (2005) examined the incidence of ALL among 
children less than 5 years in United States. Country based incidence rate were 
analysed and they found that higher incidence of ALL was observed in urban 
area than rural area (15). 
21. Totadri S et al (2016) did a retrospective analysis in tertiary care 
centre to study if the distance between the home and treating hospital will 
influence the outcome of children with ALL. The results are patients who are 
residing from rural and urban areas do not have significant difference in their 
survival (36).  
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22.Caughey RW et al (2008) did a meta-analysis to establish the 
relationship between the childhood ALL and birth weight. 32 studies and 
16501 cases of leukaemia were included in this study. Among the leukaemia 
cases, 10974 cases were ALL. Significantly positive association was noted 
between high birth weight and ALL in this study and there were no association 
between ALL and low birth weight (37). 
23. Milne E et al(2013) did a meta-analysis of data from 12 case control 
studies. The study aim was to establish the association between foet al growth 
velocity and risk of ALL. Cases and control in this study were 1680 and 3139 
respectively. In this study positive association had been observed between 
increased risks of ALL and accelerated fet al growth (38).  
24. Kong SG et al (2014) did a study regarding hyperleukocytosis in 
paediatric ALL at pusan national university hospital. Total enrolment for this 
study was 104 children. Twenty (19.2%) of 104 children had initial leukocyte 
count of >100x109/L, 11 patients had a leukocyte count of >200x109/L. 
Tcellphenotype, massivesplenomegalyand male gender were strongly 
associated with hyperleukocytosis .Patients who had initial leukocyte of   
>200x109/L had a lower EFS than those with initial leukocyte counts 100-
200x109/L. The outcome of initial leukocyte count of >200x109/Lwere very 
poor (39).  
25.İrken G et al (2006) conducted a study named “hyperleukocytosis in 
childhood ALL: complication and treatment outcome”. This study evaluated 
the outcome of ALL with respective of hyperleukocytosis (>100×10 9/L). 18% 
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of this study population had hyperleukocytosis. This study result showed 
hyperleucocytosis had poor treatment outcome in ALL (40). 
26. Sevinir B et al (2011) conducted a study to examine the incidence 
and outcome, of ALL and non-Hodgkin’s lymphoma. 214 children had ALL in 
this group in which 26.5% had hyperuricemia and 0.47% had tumor lysis 
syndrome. Hyperuricemic ALL children of this study had high tumor burden 
which affected the treatment outcome adversely (41). 
 27. Clarke RT et al (2011)did a prospective study, in their study they 
screened 12303 abstracts for eligibility criteria and included 33 studies 
(n=3084) in the analysis. All were cohort studies without control groups. They 
identified 95 presenting signs and symptoms and ranked according to their 
frequency.  More than 50% of children had five features : hepatomegaly (64%),  
splenomegaly (61%),pallor (54%),fever (53%),and bruising(52%).the 
additional features which were seen in a third to half of a children were 
recurrent infections (49%), fatigue(46%),limbpain(43%), 
hepatosplenomegaly(42%),bruising/petechiae(42%),lymphadenopathy(41%),bl
eeding tendency (38%)and rash (35%).6% of children are asymptomatic during 
the diagnosis of ALL. Hepatosplenomegaly, pallor, fever or bruising will be 
seen in 50% of children. Abdominal distension, anorexia, weight loss, 
abdominal distension were the common abdominal symptoms. Joint pain and 
limp were the common musculoskelet al features. Unexplained illness in 
children require a thorough history and detailed clinical examination which 
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include abdominal examination, palpation for lymphadenopathy and careful 
examination of skin (8). 
 28. Kulkarni KP, et al (2013) did a study to find out the clinical 
correlation, prognostic impact of pancytopenia in ALL children with their 
survival. The study shows pancytopenia at the time of diagnosis had 
significantly better outcome than others(42). 
 29. AL Sudairy R et al (2013) conducted a retrospective analysis study. 
594 patients were studied. Male predominance observed (56.4% of boys). The 
median age was 4.37. B cell ALL was observed in 89.5% and T cell ALL was 
observed in 10.5% (45). 
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STUDY JUSTIFICATION 
 The clinical profile of acute lymphoblastic leukemia in Indian 
children is varied and also there is limited data.  
 This varied presentation of ALL presents a diagnostic challenge 
to the physician. 
 Overall outcome is based on early diagnosis and early treatment. 
The initial response to the first few weeks of remission induction 
chemotherapy is of paramount importance in predicting the long 
term disease survival. 
 This study is done to analyse the clinical profile of acute 
lymphoblastic leukemia in paediatric patients and to reduce 
morbidity and mortality by early diagnosis and appropriate 
treatment.  
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AIM AND OBJECTIVES 
 To determine the clinical profile of acute lymphoblastic leukemia 
in children between 1 month -12years of age at a tertiary care 
centre - Institute of child health and hospital for children, 
Chennai, south India. 
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MATERIALS AND METHODS 
 STUDY DESIGN:   
Observational study 
 STUDY POPULATION:  
Children in study age group admitted in haematology and paediatric 
medical ward, satisfying the inclusion criteria.  
 PLACE OF STUDY:  
Department of haematology and paediatric medical ward in Institute 
of Child Health &Hospital for Children, Chennai.  
 STUDY PERIOD:  
August2017 to September 2018. 
 SAMPLE SIZE:  
One hundred and thirteen children (admitted consecutively in 
institute of child health & hospital for children with ALL are 
included in my study). 
 INCLUSION CRITERIA: 
All children aged 1month to 12years diagnosed as acute 
lymphoblastic leukemiain Institute of Child Health &Hospital for 
Children, Chennai.  
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 EXCLUSION CRITERIA:  
Children with acute lymphoblastic leukemia who have started 
treatment outside, children with relapse of acute lymphoblastic 
leukemia, children with other haematological malignancy and 
children with other malignancies. 
PROCEDURE 
Informed consent from the parent/guardian was obtained. Detailed 
information was collected regarding various patient demographic 
characteristics including detailed history, clinical examination findings and 
laboratory parameters. 
Detailed history taken in this study included fever and its duration 
irrespective of the admission in hospital, pallor, icterus, lymphadenopathy 
which was asked for by history of any swelling in the neck, axilla or groin 
region and was confirmed by clinical examination. The presence of rash and its 
type including infective, petechial or purpuric rash and abdominal distension 
for hepatomegaly, splenomegaly, ascites and mass was asked for. Swelling 
anywhere in the body other than lymphadenopathy and abdominal mass, 
especially in the cheek for parotid involvement was asked and confirmed by 
clinical examination., fatigue often not told by children but noticed by the 
mother. Abdominalpain, body ache, joint pain, difficulty in walking, bone pain 
was asked for and was confirmed by the presence of tenderness. Bleeding in 
the form of epistaxis, ecchymosis, gum bleed, melena, hematochezia, and 
hematemesis was asked for. History of seizures for the involvement of central 
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nervous system and any testicular swelling was asked for and confirmed by 
physical examination. 
 Past history of any underlying disorder that might predispose to the 
development of malignancy or syndromic disorder was obtained. Antenatal 
history and birth history including mode of delivery (delivered by labour 
natural or assisted mode or LSCS) was obtained. Birth weight was enquired 
from the mother and verified with relevant documents. Developmental history 
was asked and confirmed by developmental assessment. Family history 
including consanguinity and similar illness in the family members was 
obtained. 
 Nutritional status of the child was arrived at by measuring the height and 
weight. Length was used for children aged less than two years instead of 
height. Weight for height was calculated in children aged less than five years of 
age and BMI was calculated for children more than five years of age. The 
anthropometric measurements were plotted in the growth chart to look for 
malnutrition.  
 The history of initial symptoms was asked. Details regarding the time 
taken for the initial hospital visit where ALL was suspected and referral details 
were noted. The time taken for diagnosis from the appearance of initial 
symptoms was calculated in days. 
All the children then underwent initial investigations like complete 
blood count, peripheral smear, blood sugar, renal Function Test (serum urea, 
serum creatinine), serum electrolytes (serum sodium, serum potassium), liver 
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function tests (SGOT, SGPT), Serum uric acid, Serum Amylase, Serum LDH, 
Lipid profile(serum triglyceride, serum LDL ,serum HDL) and urine routine. 
Imaging modalities including X-ray chest, X-ray long bones, USG 
abdomen, and echocardiography are done. Blood culture and urine culture were 
done to rule out infective causes and to decide upon the choice of treatment. 
Serum viral markers, mainly hepatitis panel was done. 
 Children who are suspected cases of ALL with classical symptoms and 
signs were confirmed by bone marrow examination and CSF analysis for 
malignant cells.  
The bone marrow examination and CSF tapping were done after 
obtaining informed consent from the parents. The diagnosis was confirmed by 
flowcytometric analysis of peripheral blood or bone marrow aspirate. Further, 
immunophenotyping was also done by using the flow cytometry.  
All the above data were entered in a pre-structured Proforma.  
Ethical consideration: 
This study does not include any experimentation. Patients are informed 
of the procedure done in detail and informed consent is obtained. No one 
received any benefit, personal or professional from a commercial party directly 
or indirectly including the subject of this study. 
 STATISTICAL ANALYSIS: 
Data was entered in excel sheet. Descriptive statistics analysis was done. 
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RESULT 
A total of 113 children with ALL were included in this study 
DEMOGRAPHY 
73.45 %( 83) of the children in this study group belong to rural area and 
26.55 %( 30) of children were from urban area. The distribution of residential 
places is illustrated in figure 6.  
 
 
 
Figure 6 
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SEX DISTRIBUTION  
Out of 113 children, 60.20% are boys and 39.80% are girls. Male: female ratio 
was 1.58:1. The sex distribution is shown in figure 7. 
 
 
Figure 7 
 
Sex distribution according to immunophenotyping is shown in table18. 
Children with B cell ALL were 91 .Males constituted 54.94 %( 50) and females 
were 45.05 %( 41). The Male: female ratio was 1.21:1.Total no. of children 
with T cell ALL are 22, among them 81.81 %( 18) are maleand 18.18 %( 4) 
were female children. Male: female ratio was 4.5:1 
MALE, 60.20
%
FEMALE, 39.8
0%
sex wise distribution 
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Table 19 
Sex distribution 
 TOTAL MALE FEMALE M:F 
ALL cases 113 68(60.20%) 45(39.80%) 1.51:1 
B cell ALL 91 50(54.94%) 41(45.05%) 1.21:1 
T cell ALL 22 18(81.81%) 4(18.18%) 4.5:1 
 
The immunphenotypic sex distribution is illustrated in figure 8.  
 
Figure 8 
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AGE DISTRIBUTION 
The age range of this study group wasbetween 1 month to 12 years. 
Mean age of this study group was 4.92(yrs) with standard deviation of ± 
2.96(yrs). The median age group was 4 (yrs). The youngest child was 5 months 
of age and the oldest was 12 years. 
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The age distribution was calculated in the interval of <1 years, 1-4 years, 
5-8 years and 9-12 years. 3.53 %( 4 children) are below 1year of age, 48.67 %( 
55 children) are between 1-4 years of age, 35.40 %( 40children) are between5-
8 years and 12.40 %( 14chidren) are between 9-12 years of age. Age 
distribution is illustrated in figure 9. 
According to prognostic factor, the age group is divided into 1 to 10 yrs, 
<1year and >10 years of age group. 89 %(101 children) of children belonged to 
the good prognostic group (age group 1 year to 10years). 11 % (12children) of 
children were <1 year and >10 years of age group belong to poor prognostic 
age group. The age distribution according to prognostic value is shown in 
figure 10 
89%
4%
7%
11%
AGE DISTRIBUTION 
ACCORDING TO PROGNOSTIC FACTOR 
1yrs-10yrs . <1 yrs >10 yrs
Figure 10 
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17.7 % (20) of children in this study group were born from 
consanguineous marriage and 82.3 %( 93) were born from non-consanguineous 
marriage. 
 85.8 %( 97) were born by normal vaginal delivery, 14.2 %( 16) were 
delivered by LSCS for various causes. There were no post-dated deliveries 
noted in this study, 97.3 %( 110) were term at the time of birth and 2.7 %( 3) 
were preterm at the time of birth 
92 %( 104) children’s birth weight was normal and 8 %( 9) belonged to 
low birth weight. There were no children belonging to birth weight of more 
than 4 kg at the time of birth. 
The parameters related to consanguinity, mode of delivery, gestational 
age, and birth weight and their frequency shown in table 20. 
Table 20 
PARAMETERS PERCENTAGE 
Consanguineous 
Non consanguineous 
17.7%(20) 
82.3%(93) 
Term delivery 
Pre term delivery 
97.3(110) 
2.7%(3) 
Normal vaginal delivery 
Delivery by LSCS 
85.8%(97) 
14.2%(16) 
Low birth weight 
Normal birth weight 
Birth weight >4kg 
8%(9) 
92%(104) 
0%(0) 
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NUTRITIONAL STATUS
Two children (1.8%) in this study group had developmental delay, rest 
of the children (98.2%) attained age appropriate mile stones properly 
 
NUTRITION STATUS 
The nutritional status was calculated with weight for age according to 
WHO growth chart. 73.4 %( 83children) of children had normal nutritional 
status at the time of diagnosis. 22.12 %( 25children) children were underweight 
at the time of diagnosis. 4.42%(5 children) were overweight for their age at 
diagnosis. Nutritional status and their frequency is shown in figure 11. 
Figure 11 
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Five children (4.4%) had severe acute malnutrition at the time of 
diagnosis and four children belonged to thinness who were above 5 years ofage 
group accounting  for about  (3.5%) of study population. 
Interval between onset of symptoms and diagnosis  
The symptoms were noted by history. Time taken for the diagnosis of 
ALL from the first symptom onset irrespective of hospital admission was 
calculated in days. Mean duration was 13.13(days) with standard deviation of 
12.15(days). The median was 10(days). Minimum duration was 7 days and the 
maximum interval was 90 days. The descriptive statistics values are shown in 
table 21. 
 
Table 21 
Interval between onset of symptoms and diagnosis 
Parameters Value (days) 
Mean  13.13 
SD ±12.15 
Minimum 7 
Maximum 90 
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BLOOD GROUP 
The ABO blood group and Rh status of study children were analysed. The 
ABO blood group distribution in total ALL population and 
inimmunophenotypic distribution is shown in figure 12. 
 
Figure 12 
19.46 %( 22) of children had A blood group. B blood group consisted of 
41.60 %( 47children) of study population.32.74 %( 37children) had “O” blood 
group and AB blood group children were 6.20 % (7children). ABO blood 
group was further divided with Rh status. A+ and A- blood group were 18.58 
%( 21children) and 0.88 %( 1child). B+ and B- blood group were 38.93 %( 44 
children) and 2.64 %( 3children). O+ and O- blood group were 28.31 %( 
32children) and 4.42 %( 5 children) and AB+ and AB- blood group were 6.19 
%( 7 children) and 0%.  
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CLINICAL FEATURES  
The clinical features were divided into symptoms and signs. The 
common clinical symptoms were shown in table with frequency of occurrence. 
84.1 %( 95 children) of study population had fever as the initial symptom 
followed by abdominal distension (33.6%, 38), the frequency of other 
symptoms were seen in less than 50% of population. The observed clinical 
symptoms are tabulated with their frequency in table 22. 
Table 22 
CLINICAL FEATURES –symptoms 
Symptoms Frequency  Percentage 
Fever 95 84.1% 
Fatigue 20 17.7% 
Rash 5 4.4% 
Paleness 14 12.4% 
Icterus 1 0.9% 
Anorexia 3 2.7% 
Bone pain 13 11.5% 
Joint pain 19 16.8% 
Difficulty in walking 4 3.5% 
Abdominal distension 38 33.6% 
Abdominal pain 11 9.7% 
Facial puffiness 5 4.4% 
Breathlessness 10 8.8% 
Seizure 2 1.8% 
Headache 4 3.5% 
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Signs elicited in clinical examination with their frequencies are shown in 
table23. Pallor (52.2%) and hepatosplenomegaly(52.2%) were seen in more 
than 50% of population. Followed by lymphadenopathy and bleeding seen in 
30% and 20% of study population. Two (1.76%) children had isolated 
splenomegaly and four (3.5%) children had parotid swelling in their initial 
clinical examination. 
Table 23 
CLINICAL FEATURES –signs 
Signs Frequency Percentage 
Pallor 59 52.2% 
Bleeding 24 21.23% 
Mucous 10 8.8% 
Cutaneous 9 8% 
Others 5 4.4% 
 
Tenderness 3 2.7% 
Lymphadenopathy 34 30% 
Generalised 17 15% 
Localised 17 15% 
 
Hepatomegaly 82 72.6% 
Splenomegaly 61 54% 
hepatosplenomegaly 59 52.2% 
Isolated hepatomegaly 23 20.35% 
Parotid swelling 4 3.5% 
67 
 
 
 Frequently occurring clinical features and their percentages are 
illustrated in figure 13. 
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INVESTIGATIONS 
Chest x ray was done for all children as an initial investigation. Pleural 
effusion and mediastinal widening were noted, some children showed 
pneumonic changes in chest x ray as an initial presentation.1.8 %( 2children) 
children showed mediastinal widening, 2.7 %( 3children) showed pleural 
effusion and 2.7 %( 3children) of children had pneumonitis changes in x ray. 
92.8% (105) children had normal chest x ray finding. The x ray findings are 
shown in figure 14.  
 
Figure 14 
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LABORATORY VALUES 
HAEMOGLOBIN 
The Hb value of less than 11 gm. /dl is considered as anaemia and less 7 
gm. /dl is considered as severe anaemia. The mean Hb value is 6.98 with SD of 
2.86.Median is 6.8. 90.26 %( 102) children in this study group had Hb value of 
less than 11gm/dl and 54.86 %( 62) children had Hb value less than 7 gm. /dl at 
the time of diagnosis. The descriptive statistics values are shown in table 24. 
 
Table 24 
Haemoglobin  
Parameter Value (mg/dl) 
Mean 6.98 
SD 2.86 
Median 6.8 
<7 gm./dl 54.86% 
7-11gm/dl 35.39% 
>11gm/dl 9.73% 
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WHITE BLOOD COUNT 
The white blood count of this study population varied between 
1000/mm3 to 761000/mm3. Mean (±SD) of WBC is 55908.8(±91077.40). With 
median value of 22500. Maximum WBC count was 761000/mm3. 
24.77% of children (28 children) had normal WBC count at the time of 
diagnosis. 14.15 %of children (16 children) had WBC counts less than 
5000/mm3 WBC, 15.04 %of children (17children) had WBC counts more than 
100000/mm3 WBC. In the rest of the study group 54.86 %( 62 children) of 
children had WBC count between 5000/mm3 to 50000/mm3 and 15.92 %( 18) 
of children had WBC count between 50000/mm3 to 100000/mm3. Distribution 
of WBC is shown in figure 15. 
 
Figure 15 
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PLATELET  
The mean platelet value of this study population was 78518.6 with SD 
of ±131302.1. The median platelet value was 33000. According to the 
classification of thrombocytopenia, platelet value was subdivided into less than 
20000/mm3(33.28%,41), between 20000/mm3 to 50000/mm3(28.31%,32), 
between 50000/mm3 to 100000/mm3(12.41%,14), between100000/mm3 to 1.5 
lak/mm3(9.7%,11) and more than 1.5 lakhs/mm3(13.3%,15). 77% of study 
population had platelet value of less than 100000 cells/mm3 at the time of 
diagnosis. Distribution of platelet values shown in figure 16. 
 
 
Figure 16 
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The descriptive statistics values of WBC and platelet are shown in table 
25. 
Table 25 
Parameters WBC Platelet 
Mean  55908.8 78518.6 
SD ±91077.40 ±131302.1 
Median 22500 33000 
 
PANCYTOPENIA 
In this study, pancytopenia was defined as a combination of white blood 
count less than 4000 ×109/L, platelet count less than 100 ×109/L and 
haemoglobin value less than 11gm/dl.  
3.5% (4 children) of children had pancytopenia at the time of diagnosis 
URIC ACID  
Serum Uric acid was done for all the children in this population. Mean 
uric acid level was 5.46 with Standard deviation of ±2.67. Median value of uric 
acid was 4.9. Hyperuricemia was calculated according to the age criteria. 
28.3% (32 children)of children had elevated uric acid level according to their 
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age related value. 71.7 %( 81children) of children had normal uric acid level at 
the time of diagnosis. 
 
LDH 
Lactate dehydrogenase is used as a prognostic marker and also for diagnostic 
clue. LDH level was done in all children in this study population .Mean LDH 
value of this study population was 1003.01 with SD of ±1230.38. The median 
value was 616. 89.38 %( 101children) of children had elevated LDH level at 
the time of diagnosis.10.61 %( 12 children) of children had normal LDH level 
Summary of uric acid and LDH value is shown in table 26. 
Table 26 
URIC ACID and LDH descriptive analysis 
Parameter Uric acid LDH 
Mean 5.46 1003.01 
SD 2.67 1230.38 
Median 4.9 616 
Elevated level seen in 28.3% 89.38% 
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Uncommon presentation: 
Among the multitude of uncommon presentations of ALL seen in 
children, hepatitis, tumor lysis syndrome were observed in my studies.  
Two children presented as a case of hepatitis which occupies 1.8% of 
study population. 
One (0.9%) child had tumour lysis syndrome at the time of diagnosis 
IMMUNOPHENOTYPIC DISTRIBUTION  
The immunophenotying was done for all children in this study group to 
confirm the diagnosis.80.53 %( 91 children) of children had B cell ALL and 
rest of the children 19.46%, (22children) had T cell ALL. The frequency of 
immunophenotyping in this study are shown in table 27. 
 
Table 27 
IMMUNOPHENOTYPIC DISTRIBUTION 
ALL TYPE FREQUENCY 
B ALL 76.99%(87) 
Pro B ALL 3.5%(4) 
T ALL 18.6%(21) 
Early T Cell precursor 
ALL(ETP-ALL) 
0.9%(1) 
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B cell ALL and T cell ALL distribution of this study population is 
illustrated in figure 17 
Figure 17 
 
Four children (3.5%) had pro B ALL and one child (0.9%) had early T 
cell precursor ALL 
Common ALL Antigen (CALLA) distribution 
CD 10 marker was done for all children in this study .In my study 
among total number of 113 children with ALL, 77 %( 87children) had CALLA 
positivity in their immunophenotying. Remaining 23 %( 26 children) of 
children showed CD10 negativity. 
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B ALL and T ALL DISTRIBUTION 
B ALL T ALL
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Among children with B cell ALL 80.53% (91 children),86.81 %( 79 
children) had CALLA positivity and remaining 13.18 %(12children) of 
children were CALLA negative B cell ALL. 
Among 19.5%   (22 children) with T cell ALL, 36.36 %( 8children) of 
children had CALLA positivity and remaining fourteen cases (63.63%) were 
CALLA negative T cell ALL. CALLA distribution in total study population 
and distribution among immunophenotype is shown in figure 18.  
 
Figure 18 
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PROGNOSTIC FACTOR DISTRIBUTION 
Male sex and age group (less than one year and more than 10 years) 
were the major prognostic indicators of treatment outcome. Those with Organ 
infiltration (hepatomegaly, splenomegaly and lymphadenopathy), WBC count 
more than 50000/ mm3, platelet counts and LDH level had poor prognosis. 
Distribution of prognostic factor which accounted for poor outcome is shown 
in table 28. 
Table 28 
Prognostic factor distribution 
Prognostic factor ALL(113) B CELL (91) T CELL(22) 
Age<1yr, >10 yrs. 11%(12) 7.69%(8) 18.18%(4) 
Male 60.17%(68) 54.94%(50) 81.81%(18) 
Hepatomegaly 72.6%(82) 72.52%(66) 72.72%(16) 
Splenomegaly 54%(61) 53.84%(49) 54.54%(12) 
Lymphadenopathy 30%(34) 29.67%(27) 31.81%(7) 
WBC 
>50000/mm3 
30.97%(35) 26.37%(24) 50%(11) 
PLATELET 
<100000/mm3 
77%(87) 83.51%(76) 54.54%(12) 
Elevated LDH 89.38 %( 101) 86.81%(79) 100%(22) 
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DISCUSSION 
Acute lymphoblastic leukemia is characterised by the unrestrained 
clonal proliferation of haemopoietic precursor cells coupled with aberrant or 
arrested differentiation. Clinicians depend on the newer diagnostic modalities 
to diagnose and recognize the association between the morphology and 
immunophenotype and specific cytogenetic abnormalities. This has led to the 
development of added treatment modalities based upon specific genetic defects. 
ALL accounts for 60-80% of Childhood leukemia, and male 
preponderance is noted in children with ALL. In my study, a total of 113 
children diagnosed to have ALL were included. Out of 113 children 60.17% 
were male, 39.82% were female. The male: female ratio was 1.58: 1. Male 
predominance was noted in my study.  
 In our study 91 children have B-cell ALL. Among them 54.94% were 
male, 45.05% were female and the male: female ratio for B-cell ALL was  
1.21:1. Total children with T-cell ALL were 22, among them 81.81% were 
male, 18.18% were female and the male: female ratio was 4.5: 1. 
 Our study supports the finding of definitive male preponderance 
(60.17%, 68 children) which was as similar as been observed in other studies. It 
can also occur due to the trend of low female population in our country. The 
findings of my study were similar to the observations of other studies. The 
study done by Guru et al(2018) shows male predominance i.e. male: Female 
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ratio is 3.5:1. The study done by Kulkarni KP et al (2013) (16) showed male 
predominance with Male: Female ratio of 3.1:1 
In our study B-cell ALL(80.53%) was more commonly found in 
children than T-cell ALL(19.46%) as similar to other studies. Sousa DW et al 
(2015) (26), conducted a study in 76 patients who were under the age of 19 years 
and positive for ALL. In their study B cell immunophenotype ALL was found 
in 89.5% of patients and T immunophenotype ALL was found in 10.5% of 
patients. B cell immunophenotype is the commonest type in people who are 
less than 19 years.  
In our study peak incidence of paediatric ALL were reported in the age 
group of 1-4 years of age. The number of children who were affected in this 
age group was 48.6%. Better prognosis was observed in children belonging to 
1-10 years of age. 
Sousa DW et al (2015) (26) conducted a study in 76 patients under 19 
years of age and diagnosed with ALL. In their study Patients between 1 and 9 
years of age were associated with more favourable prognosis similar to my 
study. Similar observations were made with Guru FR et al (2018) (5), Arya LS 
et al (2011)(18) and Ahirwar R et al (2018)(29). 
82.3% (93 children) were born from non-consanguineous marriage and 
17.7% (20 children) were born from consanguineous marriage. 
 In our study, Majority of children affected with ALL were born through 
normal vaginal delivery (85.8 %,) .The rest (14.2 %,) were born through LSCS.  
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Majority of children with ALL had normal birth weight (92 %,) and the 
rest of 8%, had low birth weight. 97.3% of children were born at term and rest 
2.7% children were born at preterm. Mean interval between diagnosis and 
onset of symptoms was 13.13 ± 12.15 days. 
 In our study 73.4% (83 children) had normal nutritional status at the 
time of diagnosis, 22.12% (25 children) were underweight. 4.42 %( 5children) 
were overweight at the time of diagnosis. The study done by Kumar N et al 
(2017) (34) showed that 50% of children were undernourished at the time of 
diagnosis and no overweight children were observed in their studies. 
 In our study B blood group was commonly found in children affected 
with ALL accounting for 41.5%. In the study done by TavasolianF et al (2014) 
(33) showed higher number of ALL patients had AB blood group  
(p value <0.001). Li SY et al (2015)(28) compared the clinical features of ALL 
in male and female patients in southern china, in their study the most frequently 
occurring blood group was O blood group, but in my study it was B blood 
group. 
Among the variety of symptoms the commonest complaint recorded in 
my study was fever, 84.1% have fever. Abdominal distension was the second 
most common symptom observed in the children in my study, 33.6% had 
abdominal distension. The other signs and symptoms were fatigue, rash, 
paleness, icterus, anorexia, bone pain, joint pain, difficulty in walking, 
abdominal pain, nausea, puffiness, breathlessness, seizures, and headache.  
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Pandian G et al (2018) (25) did a prospective study in GRH Madurai. In 
his study fever was the most common symptom as similar to my study. The 
study of Siddaiahgari SR et al (2015) (6) also had the same observation. 
In our study among variety of signs pallor was the sign which was 
commonly observed in majority of children with ALL. 72.6% of children 
affected with ALL had hepatomegaly. The second most common sign seen was 
pallor, 52.2% had pallor. The other signs were bleeding, enlarged lymph nodes 
which were generalised or localised, hepatomegaly, splenomegaly, 
hepatosplenomegaly and parotid swelling. 
Shalal HH et al (2017), (7) did a retrospective study in 55 patients to 
show initial presenting features of ALL. In his study fever and pallor were the 
most common presenting features similar to my study. 
 Chest x ray was the initial investigation. Pleural effusion, pneumonia, 
mediastinal widening  were the findings seen in chest x ray. In my study2.7% 
of children had pneumonia. 
In our study 1.8% children had mediastinal widening. In the study of 
Siddaiahgari SR et al (2015) (6), 4.5% of study population had mediastinal 
involvement.In the study of Shalal HH et al (2017) (7), 7.2% of study population 
had mediastinal widening. 
In our study 2.7% of children had Pleural effusion. In the study of Shalal 
HH et al (2017) (7), 1.8% of study population had pleural effusion. 
82 
 
Blood investigations such as haemoglobin, WBC count, platelet count, 
uric acid and LDH were done in my study. 
In our study 90.26 % had anaemia at the time of diagnosis and 54.68% 
with ALL had severe anaemia (haemoglobin value less than 7gms /dl). 
Sousa DW et al (2015) (26) conducted a study in 76 patients who were 
under the age of 19 years and positive for ALL. In their study anaemia was 
found in 85% of patients. The similar observation was noted in my study, 
anaemia is seen in almost 90.26% of population among which 54.68 %( 62 
children) were severely anaemic. 
In our study majority of children (57.52%)had WBC counts in the range 
of 5000-50,000/mm3.Hyperleukocytosis was observed in 15% with WBC count 
more than 100000/mm3. 
The study of Shalal HH et al (2017) (7) had 16.4% of study population 
with hyperleukocytosis. Kong SG, et al (2014) (39) did a study regarding 
hyperleukocytosis in pediatric ALL at pusan national university hospital. Total 
enrolment of this study was 104 children. Twenty (19.2%) of 104 children had 
initial leukocyte count of more than 100x109, 11 patients had a leukocyte count 
of  more than 200x109/L. T cell phenotype, massive splenomegaly and male 
gender were strongly associated with hyperleukocytosis. 
In our study among 113 children, 33.6% had platelet count less than 
20,000/mm3 with severe thrombocytopenia. In the study done by Shalal HH et 
al (2017) (7) 25.5% of cases had severe thrombocytopenia. Also the study by 
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Pahloosye A et al (2011) (17) 19% of cases had severe thrombocytopenia in their 
study population. 
In our study 3.5% had pancytopenia at the time of diagnosis. In the 
study of Kulkarni KP, et al (2013) (42), 11.02% had pancytopenia with ALL, All 
had better prognosis. 
 In our study hyperuricemia was observed in 28.3% of children at the 
time of diagnosis similar to the below mentioned study of Sevinir B et al 
(2011) (41).The hyperuricemic children in my study have high tumour burden 
and in such cases the treatment outcome was also affected adversely. 
Sevinir B et al (2011) (41) conducted a study to examine the incidence 
and outcome with ALL and non-Hodgkin’s lymphoma. 214 children had ALL 
in this group in which 26.5% had hyperuricemia and 0.47% had tumorlysis 
syndrome. Hyperuricemic ALL children of this study had high tumor burden 
which affected the treatment outcome adversely. 
 LDH is used as a prognostic marker and in diagnosis; maximum number 
of children 89.38% had elevated LDH levels. 
Uncommon presentations were hepatitis and tumour lysis syndrome 
which was seen in 1.8% and 0.9% respectively. Tumor lysis syndrome of 
32.04% was observed in the study of Siddaiahgari SR et al (2015) (6). 
Siddaiahgari SR et al (2015) (6) also noted tumor lysis syndrome in 
hyperleukocytosis patients comprising 22% of the study population. In my 
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study 15% of children had hyperleukocytosis, among them only 0.9% showed 
tumor lysis syndrome. 
According to immunophenotypic distribution 80.53% (91 children) had 
B-cell ALL and 19.46% (22 children) had T-cell ALL. B-cell ALL was the 
commonest leukaemia observed in my study. This observation was similar to 
the other studies conducted in India. Siddaiahgari SR et al (2015) (6) observed 
that the common immunophenotype was B cell ALL. Guru et al (2018) (5) study 
had 88.6% of B cell ALL. 
In our study 77% were CALLA positive and remaining 23% were 
CALLA negative. This observation was similar with the study done by Pandian 
G et al (2018) (25) in which 91.7% of ALL showed CD10 positivity. In the study 
done by Siddaiahgari SR et al (2015) (6), in which 88.75% were CALLA 
positive and 11.25% were CALLA negative. 
In the study of Khan AH et al (2015) (23) 93.1% of B cell ALL expressed 
CD10 and 45.4% of T cell ALL expressed CD10.  
CD 10 distribution according to immunophenotyping was observed in 
my studies. 86.81% of children in B cell ALL had CD 10 positivity and 36.36 
of children in T cell ALL had CD10 positivity. Remaining 13.18% of children 
in B cell ALL and 63.63% of children in T cell ALL were CD10 negative. 
In our study, the children belonging to age group less than 1 year were 
3.53% and the children who were more than 10 years are 7.07%, accounting for 
a total of 11%had poor prognosis. The other important factors determine the 
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prognosis were Male sex noted in 60.17%, Hepatomegaly noted in 60.17%, 
Splenomegalynoted in 54%, Lymphadenopathy noted in 30%, WBC more than 
50000/mm3 was seen in 30.97%, Platelet less than100000/mm3 was seen in 
77% and Elevated LDH was observed in 89.38%. In the study conducted by 
Arya LS et al (2011) (18) andPahloosye A et al (2011),the above mentioned 
prognostic  factors were as similar as my study which determined the prognosis 
of the children (17). 
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LIMITATIONS 
 Children who are aged between 1 month to 12 years are alone included 
in this study. 
 It include only 113 children due to availability of cases and time 
constraint. 
 This study is a hospital based study which is not strictly representative  
of the background population. 
 Karyotyping and Cytogenetics abnormalitiesas a prognostic factor of 
ALL could not be done. 
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CONCLUSION 
ALL was found to be a most frequent childhood haematological neoplasm.  
In our study, 
 ALL was commonly seen in the age group of   1 - 4 years (48.67%) 
 Most of the children (89%) belong to good prognostic age group of 1-10 
years 
 Male predominance(60.20%) was noted in this study. 
 B cell ALL (80.53%) was noted more commonly than T cell ALL 
(19.46%) 
 Majority of the children (77%) with ALL expressed CD10 antigen. 
 Most common presenting symptom was fever seen in 84.1% of children 
and sign was pallor and hepatosplenomegaly seen in 52.2% and 52.2% 
respectively. 
 Most of the children with ALL were anaemic(90.26%). Severe anaemia 
was noted in 54.68%. 
 Hyperleukocytosis was observed in 15%. 
 Severe thrombocytopenia was observed in 36%.  
 Hyperuricemia was observed in 28%.  
 Elevated LDH level was observed in 89.38% at the time of diagnosis. 
 Uncommon presentations were hepatitis (1.8%) and tumour lysis 
syndrome (0.9%) 
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 CLINICAL   PROFILE OFACUTE LYMPHOBLASTIC LEUKEMIA 
INCHILDREN. 
PROFORMA FOR THE STUDY 
Name:                                         Age:               Sex:                     
Urban/Rural:                      
Inpatient no:        Hematology no: 
Adresss:                                        
Detailed History of   presenting illness 
Fever 
Bleeding manifestation 
(Epistaxis, petechiae, purpura, ecchymosis, Gum bleed,Melena ) 
Swelling(cervical, axillary, inguinal) 
Pallor 
Abdominal distension 
Bone pain 
General body pain 
Joint pain 
Inability to walk  
Breathlessness  
Abdominal pain 
Seizure 
Others  
Past history: 
Developmental history: 
Immunization history: 
Family history: 
Treatment history: 
Clinical Examination: 
General examination  
Pallor 
lymphadenopathy:(localised, generalised) 
 Icterus: 
Pedal edema: 
Cyanosis : 
Clubbing : 
 
Head to foot examination 
 Oral cavity 
 Eyes  
 Ears  
 Limbs 
 Bone and joints 
 Spine 
 Skin  
 External bleeds (skin, mucocutaneous) 
 Genitals (testicular swelling) 
ANTHROPOMETRY 
Weight:                                       Height/length:   
 Head Circumference:   Mid arm circumference 
VITAL SIGNS  
Heart rate:                     Respiratory rate: 
Blood pressure:                       Body temperature:   
 SYSTEM EXAMINATION: 
Cardiovascular system 
 Respiratory system 
Abdomen examination 
Central nervous system   
  Investigations 
Peripheral smear 
Bone marrow cytology 
Flow cytometry  
Complete hemogram  
Haemoglobin 
Total white blood cell count 
 Differential Count 
Platelets count 
Pcv 
Rbc 
Mcv 
Mch 
Mchc 
Rdw 
Renal function test 
Blood sugar  
Serum urea 
Serum creatinine 
Serum electrolyte 
Serum sodium 
Serum potassium 
Liver function test 
SGOT 
SGPT 
Serum bilirubin 
Serum Amylase  
Serum calcium 
Serum phosphorus 
Serum Uric acid 
Serum LDH 
Viral marker 
Urine analysis  
Urine albumin, sugar, deposits 
Stool analysis 
 Stool for occult blood 
Chest x ray   X ray long bones  
Ultrasonography abdomen 
Echocardiography    CSF analysis  
Blood group   Others 
 PATIENT INFORMATION SHEET 
PLACE OF STUDY:   Institute Of Child Health and Hospital for Children, 
Egmore, Chennai-8 
NAME OF INVESTIGATOR:  Dr.P.Balamurugan. 
NAME OF PARTICIPANT    AGE:  
 SEX:  
HOSPITAL NO:     HEMATOLOGY NO: 
STUDY TITLE:Clinical Profile of Acute Lymphoblastic Leukemia 
We request you to participate in the study 
Aim of the study  
  This study aims to determine the  clinical profile of acute 
lymphoblastic leukemia in children, The purpose of this study is to 
determine the varied presentation of acute lymphoblastic leukemia 
Methodology  
Your child’s symptoms and signs will be elicited and necessary blood 
investigations, bone marrow aspiration study, x ray study, computed 
tomography study and cerebrospinal fluid analysis will be done.  
Can I refuse to participate in the study ? 
Participation in the study is purely voluntary. You may refuse to participate 
or withdraw from the study at any time . in both cases the treatment and 
care your child receives from this hospital will not be affected in any 
mannaer. 
Benefits and harms of participating in the study 
Your child will not benefits directly by participating in this study. But by 
way of participating in this study, your child is contributing to updation of 
 science which may benefit her/him and all other patients with this disease in 
future. 
 Confidentiality   
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Subject rights  
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. The results 
of the special study may be intimated to you at the end of the study period . 
Can I contact the investigator? 
 If you wish further information regarding your child’s rights as a 
research participant, You can contact the investigator in the mobile number 
or address mentioned below 
 Principal investigator : Dr.P.Balamurugan 
 Mobile number : 9698364693 
 Contact address : post graduate student M.D., pediatrics , institute of       
child health and hospital for children, egmore, Che nnai. 
 
 
Signature of investigator                                              Signature of 
participant 
 
 
Date: 
Place: 
  
 
 
 
  
 
 
 
 INFORMED CONSENT FORM 
STUDY PLACE:  Institute Of Child Health And Hospital For Children,   
Egmore, Chennai-8 
TITLE OF THE STUDY:  Clinical Profile   Of   Acute Lymphoblastic 
Leukemia In Children 
NAME OF THE INVESTIGATOR  :  Dr.P.Balamurugan.    
NAME OF THE PARTICIPANT:  AGE:   SEX: 
HOSPITAL NUMBER:  HEMATOLOGY  NO: 
1. I have read and understood this consent form and the information 
provided to me regarding the participation in the study.  
2. I have had the consent document explained to me.  
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the 
investigator.  
5. I will allow my child to cooperate with the investigator and undergo 
clinical tests subjected during the study whole heartedly. 
6. I have been advised about the risks associated with my participation in 
this study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if  I suffer unusual symptoms.  
8. I have not participated in any research study in the past. 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital.  
 10. I am also aware that the investigator may terminate my participation in 
the study at any time, for any reason, without my consent.  
11. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented.  
12. I have understand that  my  identity will be kept confidential if my data 
are publicly presented  
13. I have had my questions answered to my satisfaction.  
14. I have decided to be in the research study.  
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given 
in this document has been clearly explained to me and understood by me, I 
will be given a copy of this consent document. For adult participants:  
Name and signature / thumb impression of the participant /parents/guardian  
Name _________________________ Signature_________________ 
Date________________  
Name and Signature of impartial witness:  
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of the investigator or his representative obtaining 
consent:  
Name _________________________ Signature_________________ 
Date________________  
 
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
